The CCTG CO.26 study was the first to demonstrate that anti-PD-L1 combined with anti-CTLA-4 could extend OS in patients with refractory MSS CRC compared to best supportive care (BSC) (235). Here, CTLA4 is linked to colorectal carcinoma.